Moderna:撤回流感和新冠组合疫苗候选品的上市申请

老虎资讯综合
Yesterday

Moderna表示,已自愿撤回针对mRNA-1083的生物制品许可证申请,该疫苗是针对50岁及以上成人的流感和新冠组合疫苗候选品。

该公司称,在其研究性季节性流感疫苗mRNA-1010的晚期试验中获得疫苗有效性数据后,将重新提交BLA。Moderna预计将在今夏公布mRNA-1010试验的中期数据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10